Advertisement

Clinical Pharmacokinetics

, Volume 47, Issue 7, pp 463–474 | Cite as

Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

  • Pertti J. NeuvonenEmail author
  • Janne T. Backman
  • Mikko Niemi
Review Article
First Online:

Abstract

HMG-CoA reductase inhibitors (statins) dose-dependently lower both the level of low-density lipoprotein cholesterol and risk of cardiovascular disease. In 2004, the UK approved a low-dose over-the-counter (OTC) simvastatin, but the US has rejected applications for non-prescription preparations of statins. The pharmacokinetics and interaction potentials of the possible OTC candidate statins simvastatin, lovastatin, fluvastatin and pravastatin are clearly different. Simvastatin and lovastatin are mainly metabolized by cytochrome P450 (CYP) 3A, fluvastatin is metabolized by CYP2C9, and pravastatin is excreted largely unchanged. Several cell membrane transporters can influence the disposition of statins, e.g. the organic anion transporting polypeptide (OATP) 1B1 enhances their hepatic uptake. The c.521T>C (p.Vall74Ala) genetic polymorphism of SLCO1B1 (encoding OATP1B1) considerably increases the plasma concentrations of simvastatin acid and moderately increases those of pravastatin but seems to have no significant effect on fluvastatin. Strong inhibitors of CYP3A (itraconazole, ritonavir) greatly (up to 20-fold) increase plasma concentrations of simvastatin, lovastatin and their active acid forms, thus enhancing the risk of myotoxicity. Weak or moderately potent CYP3A inhibitors such as verapamil, diltiazem and grapefruit juice can be used cautiously with low doses of simvastatin or lovastatin, but their concomitant use needs medical supervision. Potent inducers of CYP3A can greatly decrease plasma concentrations of simvastatin and simvastatin acid, and probably those of lovastatin and lovastatin acid. Although fluvastatin is metabolized by CYP2C9, its concentrations are changed less than 2-fold by inhibitors or inducers of CYP2C9. Pravastatin plasma concentrations are not significantly affected by any CYP inhibition and only slightly affected by inducers. Ciclosporin inhibits CYP3A, P-glycoprotein and OATP1B1. Gemfibrozil and its glucuronide inhibit CYP2C8 and OATP1B1. Ciclosporin and gemfibrozil increase plasma concentrations of statins and the risk of their myotoxicity, but fluvastatin seems to carry a smaller risk than other statins. Inhibitors of OATP1B1 may decrease the benefit-risk ratio of simvastatin, lovastatin and pravastatin by interfering with their (active acid forms) entry into hepatocytes. Understanding the differences in the pharmacokinetics and interaction potential of various statins helps in their selection for possible non-prescription status. On the pharmacokinetic basis, fluvastatin and pravastatin can be better choices than simvastatin or lovastatin for an OTC statin.

Keywords

Statin Simvastatin Pravastatin Lovastatin Fluvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  2. 2.
    Bays H. Statin safety: an overview and assessment of the data — 2005. Am J Cardiol 2006; 97 Suppl.: 6C–26CPubMedCrossRefGoogle Scholar
  3. 3.
    Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582–7PubMedCrossRefGoogle Scholar
  4. 4.
    OTC statins: a bad decision for public health [editorial]. Lancet 2004; 363: 1659CrossRefGoogle Scholar
  5. 5.
    Gotto AM. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. Clin Pharmacol Ther 2005; 78: 213–7PubMedCrossRefGoogle Scholar
  6. 6.
    Strom BL. Statins and over-the-counter availability. N Engl J Med 2005; 352: 1403–5PubMedCrossRefGoogle Scholar
  7. 7.
    Davidoff F. Primary prevention with over-the-counter statins: a cautionary tale. Clin Pharmacol Ther 2005; 78: 218–20PubMedCrossRefGoogle Scholar
  8. 8.
    Rashid S. Should cholesterol-lowering medications be available in Canada without a prescription. Can J Cardiol 2007; 23: 189–93PubMedCrossRefGoogle Scholar
  9. 9.
    Gotto AM. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Circulation 2006; 114: 1310–4PubMedCrossRefGoogle Scholar
  10. 10.
    Barter PJ, Rye KA. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins. Circulation 2006; 114: 1315–20PubMedCrossRefGoogle Scholar
  11. 11.
    Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32: 403–25PubMedCrossRefGoogle Scholar
  12. 12.
    Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26–37PubMedCrossRefGoogle Scholar
  13. 13.
    Sirtori CR. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther 1993; 60: 431–59PubMedCrossRefGoogle Scholar
  14. 14.
    Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996; 125: 990–1000PubMedGoogle Scholar
  15. 15.
    Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33: 537–46PubMedCrossRefGoogle Scholar
  16. 16.
    Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71–105PubMedCrossRefGoogle Scholar
  17. 17.
    Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565–81PubMedCrossRefGoogle Scholar
  18. 18.
    Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263–81PubMedCrossRefGoogle Scholar
  19. 19.
    Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117–26PubMedCrossRefGoogle Scholar
  20. 20.
    Singhvi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239–43PubMedCrossRefGoogle Scholar
  21. 21.
    Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39: 397–412PubMedCrossRefGoogle Scholar
  22. 22.
    Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–41PubMedCrossRefGoogle Scholar
  23. 23.
    Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53PubMedCrossRefGoogle Scholar
  24. 24.
    Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not of fluvastatin. Clin Pharmacol Ther 2006; 80: 356–66PubMedCrossRefGoogle Scholar
  25. 25.
    Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873–9PubMedCrossRefGoogle Scholar
  26. 26.
    Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74: 186–94PubMedCrossRefGoogle Scholar
  27. 27.
    Kim KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47: 87–93PubMedCrossRefGoogle Scholar
  28. 28.
    Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477–83PubMedCrossRefGoogle Scholar
  29. 29.
    Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–82PubMedCrossRefGoogle Scholar
  30. 30.
    Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56–60PubMedCrossRefGoogle Scholar
  31. 31.
    Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP 3A4 substrate simvastatin. Clin Pharmacol Ther 2000; 68: 384–90PubMedCrossRefGoogle Scholar
  32. 32.
    Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225–9PubMedCrossRefGoogle Scholar
  33. 33.
    Backman JT, Kyrklund C, Kivistö KT. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122–9PubMedCrossRefGoogle Scholar
  34. 34.
    Kyrklund C, Backman JT, Kivistö KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340–5PubMedCrossRefGoogle Scholar
  35. 35.
    Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592–7PubMedCrossRefGoogle Scholar
  36. 36.
    Kyrklund C, Backman JT, Neuvonen M, et al. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004; 57: 181–7PubMedCrossRefGoogle Scholar
  37. 37.
    Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538–44PubMedCrossRefGoogle Scholar
  38. 38.
    Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191–9PubMedGoogle Scholar
  39. 39.
    Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxyl acids is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56: 120–4PubMedCrossRefGoogle Scholar
  40. 40.
    Matsushima S, Maeda K, Kondo C, et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 2005; 314: 1059–67PubMedCrossRefGoogle Scholar
  41. 41.
    Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260–77PubMedCrossRefGoogle Scholar
  42. 42.
    Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787–802PubMedCrossRefGoogle Scholar
  43. 43.
    Tirona RG. Ethnic differences in statin disposition. Clin Pharmacol Ther 2005; 78: 311–6PubMedCrossRefGoogle Scholar
  44. 44.
    Sakaeda T, Fujino H, Komoto C, et al. Effect of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharmaceut Res 2006; 23: 506–12CrossRefGoogle Scholar
  45. 45.
    Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharmaceut Res 2001; 18: 800–6CrossRefGoogle Scholar
  46. 46.
    Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci U S A 1982; 79: 3037–41PubMedCrossRefGoogle Scholar
  47. 47.
    Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering: morning versus evening statin administration. Ann Pharmacother 2007; 41: 106–10PubMedGoogle Scholar
  48. 48.
    Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355–61PubMedCrossRefGoogle Scholar
  49. 49.
    Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRefGoogle Scholar
  50. 50.
    Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297: 861–7PubMedGoogle Scholar
  51. 51.
    Koga T, Shimada Y, Kuroda M, et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 115–20PubMedCrossRefGoogle Scholar
  52. 52.
    Buckett L, Davidson R, Dunkley C, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [abstract]. Atherosclerosis 2000; 151: 41CrossRefGoogle Scholar
  53. 53.
    Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689–723PubMedCrossRefGoogle Scholar
  54. 54.
    Kivistö KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceut Res 2007; 24: 239–47CrossRefGoogle Scholar
  55. 55.
    Mangravite LM, Thorn CF, Kraus RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenom J 2006; 6: 360–74CrossRefGoogle Scholar
  56. 56.
    Kivistö KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523–5PubMedCrossRefGoogle Scholar
  57. 57.
    Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554–65PubMedCrossRefGoogle Scholar
  58. 58.
    Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415–21PubMedCrossRefGoogle Scholar
  59. 59.
    Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429–40PubMedCrossRefGoogle Scholar
  60. 60.
    Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphism) in a hepatic drug uptake transporter: what’s it all about? Clin Pharmacol Ther 2004; 75: 381–5PubMedCrossRefGoogle Scholar
  61. 61.
    Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic MRP2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801–8PubMedCrossRefGoogle Scholar
  62. 62.
    Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 65: 78–86Google Scholar
  63. 63.
    Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375–80PubMedCrossRefGoogle Scholar
  64. 64.
    Niemi M, Neuvonen PJ, Hofmann U, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 2005; 15: 303–9PubMedCrossRefGoogle Scholar
  65. 65.
    Neuvonen PJ, Jalava M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61PubMedCrossRefGoogle Scholar
  66. 66.
    Jacobson TA. Comparative interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140–6PubMedCrossRefGoogle Scholar
  67. 67.
    Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in seronegative volunteers: ACTG study A5047. AIDS 2002; 16: 569–77PubMedCrossRefGoogle Scholar
  68. 68.
    Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391–400PubMedCrossRefGoogle Scholar
  69. 69.
    Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369–77PubMedCrossRefGoogle Scholar
  70. 70.
    Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267–74PubMedCrossRefGoogle Scholar
  71. 71.
    Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92PubMedCrossRefGoogle Scholar
  72. 72.
    Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007; 81: 679–84PubMedCrossRefGoogle Scholar
  73. 73.
    Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004; 75: 101–9PubMedCrossRefGoogle Scholar
  74. 74.
    Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732–4PubMedGoogle Scholar
  75. 75.
    Åsberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367–78PubMedCrossRefGoogle Scholar
  76. 76.
    Park JW, Siekmeier R, Lattke P, et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001; 6: 351–61PubMedCrossRefGoogle Scholar
  77. 77.
    Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209–15PubMedCrossRefGoogle Scholar
  78. 78.
    Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80A–83APubMedCrossRefGoogle Scholar
  79. 79.
    Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397–402PubMedCrossRefGoogle Scholar
  80. 80.
    Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118–27PubMedGoogle Scholar
  81. 81.
    Fukazawa I, Uchida N, Uchida E, et al. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004; 57: 448–55PubMedCrossRefGoogle Scholar
  82. 82.
    Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004; 59: 879–82PubMedCrossRefGoogle Scholar
  83. 83.
    Sugimoto R, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518–24PubMedCrossRefGoogle Scholar
  84. 84.
    Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet 1998; 351: 1929–30PubMedCrossRefGoogle Scholar
  85. 85.
    Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Engl J Med 1995; 333: 664–5PubMedCrossRefGoogle Scholar
  86. 86.
    Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol 2003; 10: 172–4PubMedGoogle Scholar
  87. 87.
    Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997; 277: 296–7PubMedCrossRefGoogle Scholar
  88. 88.
    Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann Intern Med 2004; 140: W31PubMedGoogle Scholar
  89. 89.
    Roten L, Schoenenberger RA, Rrahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38: 978–81PubMedCrossRefGoogle Scholar
  90. 90.
    Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 47: 956–65CrossRefGoogle Scholar
  91. 91.
    Rahri AJ, Valkonen MM, Vuoristo MR, et al. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother 2004; 38: 719Google Scholar
  92. 92.
    Vlahakos DV, Manginas A, Chilidou D, et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002; 73: 1962–4PubMedCrossRefGoogle Scholar
  93. 93.
    Molden E, Andersson RS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy 2007; 27: 603–7PubMedCrossRefGoogle Scholar
  94. 94.
    Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care 2000; 14: 13–8CrossRefGoogle Scholar
  95. 95.
    Cheng CH, Miller C, Lowe C, et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 59: 728–30PubMedGoogle Scholar
  96. 96.
    Granfors MT, Wang JS, Rajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98: 79–85PubMedCrossRefGoogle Scholar
  97. 97.
    Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002; 41: 1195–211PubMedCrossRefGoogle Scholar
  98. 98.
    Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66: 358–66PubMedCrossRefGoogle Scholar
  99. 99.
    Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 2004; 62: 670PubMedCrossRefGoogle Scholar
  100. 100.
    Bailey DG, Dresser GR. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4: 281–97PubMedCrossRefGoogle Scholar
  101. 101.
    Wang JS, Neuvonen M, Wen X, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002; 30: 1352–6PubMedCrossRefGoogle Scholar
  102. 102.
    Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228–36PubMedCrossRefGoogle Scholar
  103. 103.
    Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34: 191–7PubMedCrossRefGoogle Scholar
  104. 104.
    Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999; 75: 359–60PubMedGoogle Scholar
  105. 105.
    Hirano M, Maeda R, Shitara Y, et al. Drug-drug interaction between pravastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229–36PubMedCrossRefGoogle Scholar
  106. 106.
    Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40: 316–23PubMedCrossRefGoogle Scholar
  107. 107.
    Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054–62PubMedCrossRefGoogle Scholar
  108. 108.
    Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–90PubMedCrossRefGoogle Scholar
  109. 109.
    Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate-statin versus gemfibrozil-any statin. Am J Cardiol 2005; 95: 120–2PubMedCrossRefGoogle Scholar
  110. 110.
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(8A): 52C–60CPubMedCrossRefGoogle Scholar
  111. 111.
    Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197–207PubMedGoogle Scholar
  112. 112.
    Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410–3PubMedCrossRefGoogle Scholar
  113. 113.
    Ichimaru N, Takahara S, Rokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417–23PubMedCrossRefGoogle Scholar
  114. 114.
    Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21PubMedCrossRefGoogle Scholar
  115. 115.
    Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288–95PubMedCrossRefGoogle Scholar
  116. 116.
    Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors [published erratum appears in Ann Pharmacother 2001; 35: 1296]. Ann Pharmacother 2001; 35: 1096–107PubMedCrossRefGoogle Scholar
  117. 117.
    Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553–64PubMedCrossRefGoogle Scholar
  118. 118.
    Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J–34JPubMedCrossRefGoogle Scholar
  119. 119.
    Page 2nd RL, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV. Drug-drug interactions. Circulation 2005; 111: 230–9PubMedCrossRefGoogle Scholar
  120. 120.
    Lindenfeld J, Page 2nd RL, Zolty R, et al. Drug therapy in the heart transplant recipient: part III. Common medical problems. Circulation 2005; 111: 113–7PubMedCrossRefGoogle Scholar
  121. 121.
    Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70PubMedCrossRefGoogle Scholar
  122. 122.
    Tornio A, Pasanen MR, Laitila J, et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 2005; 97: 104–8PubMedCrossRefGoogle Scholar
  123. 123.
    Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24: 285–90PubMedCrossRefGoogle Scholar
  124. 124.
    Kim M-J, Nafziger AN, Kashuba ADM, et al. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol 2006; 62: 431–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Pertti J. Neuvonen
    • 1
    Email author
  • Janne T. Backman
    • 1
  • Mikko Niemi
    • 1
  1. 1.Department of Clinical PharmacologyUniversity of Helsinki and Helsinki University Central HospitalHelsinkiFinland

Personalised recommendations

Cite article

Buy options